Eli Lilly and Company (NYSE: LLY) discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Company Overview
- Market Cap: 412.743 billion
- PE Ratio: 69.29
- EPS: 6.27
- Dividend Yield: 1.04%
Recent Trends And 2023 Outlook
Eli Lilly’s stock is up 31% in 2022, an uncommon bright spot in a down market. The company benefited from a third-quarter launch of its type 2 diabetes drug, Mounjaro, plus growth from breast cancer drug Verzenio, diabetes drug Trulicity, migraine drug Emgality, and others.
The pharma company’s revenue grew 7% on a constant-currency basis in the third quarter. Earnings per share in the same quarter increased 12% on a non-GAAP basis.
Analysts largely expect Lilly’s momentum to continue, thanks to a strong product pipeline. Before the end of 2023, Lilly should launch four more products plus another major indication for Mounjaro. One product to watch is Donanemab, a treatment for early-stage Alzheimer’s patients.
Lilly EVP and CEO Anat Ashkenazi says the product portfolio can support “top-tier, volume-driven revenue growth” through 2030. In 2023, the company expects $30.3 to $30.8 billion in revenue and non-GAAP earnings per share of $8.10 to $8.30. Both ranges show growth from expected year-end 2022 results—$28.5 to $29 billion in revenues and $7.70 to $7.85 in non-GAAP earnings per share.
Lilly does pay a dividend, yielding about 1.04%. Shareholders have enjoyed dividend increases in each of the last eight years. The company’s three-year annualized dividend growth is nearly 15%. Therefore, LLY is one of the best pharmaceutical stocks to own for this year and long term.
